HealthNutrition
Hospitals Under Pressure to Improve Patient Meals
Hospitals are facing increased scrutiny regarding the nutritional quality of the meals they serve to patients. Both federal initiatives and ...
about 1 month ago
HealthNutrition
New Oral GLP-1 Agonist Shows Promise in Obesity Treatment
6 months agoUS
Structure Therapeutics has announced positive topline data from its ACCESS program for aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist. The studies show promising results in weight loss for individuals with obesity or overweight with related co-morbidities.
Key Insights
•
Aleniglipron achieved a placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at the 120 mg dose in the Phase 2b ACCESS study.
•
The exploratory ACCESS II study showed a placebo-adjusted mean weight loss of up to 15.3% (35.5 lbs) with the 240 mg dose.
•
A lower starting dose of 2.5 mg in the Body Composition Study improved tolerability, with no adverse event-related treatment discontinuations.
•
Data supports advancement to Phase 3 clinical development planned for mid-2026.
Why this matters: Aleniglipron offers a potentially accessible and scalable oral treatment option for obesity, addressing a significant unmet need. The absence of a weight loss plateau at 36 weeks is particularly encouraging.
In-Depth Analysis
Aleniglipron (GSBR-1290) is an investigational orally-available, small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor. The ACCESS clinical program included the Phase 2b ACCESS study, the ACCESS II study, the Body Composition study, and the ACCESS open label extension (OLE) study.
Phase 2b ACCESS Study: Participants achieved statistically significant weight loss with various doses. At Week 36, 86% of participants in the 120 mg dose cohort achieved at least 5% weight loss, and 70% achieved at least 10% weight loss. Improvements in systolic blood pressure and HbA1c were also noted.
ACCESS II Study: Higher doses of aleniglipron led to significant weight loss. The placebo-adjusted mean percent change in body weight at 36 weeks was -15.3% with the 240 mg dose.
Body Composition Study: Starting with a lower dose of 2.5 mg improved tolerability.
ACCESS Open-Label Extension Study: Showed continuing weight loss in all dose cohorts out to 44 weeks, with no evidence of a weight loss plateau.
The company plans to request a meeting with the FDA in the first half of 2026 to finalize the Phase 3 design and intends to initiate the Phase 3 program by mid-2026.
FAQs
•
Q: What is aleniglipron?
Aleniglipron is an investigational orally-available, small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor being developed by Structure Therapeutics for the treatment of obesity.
•
Q: What were the main findings of the ACCESS clinical program?
The ACCESS program demonstrated clinically meaningful and statistically significant weight loss, with good tolerability, supporting advancement to Phase 3 clinical development.
Key Takeaways
•
Aleniglipron shows promise as an oral treatment option for obesity, potentially expanding access to treatment.
•
The drug demonstrated significant weight loss and a favorable safety profile in clinical trials.
•
Phase 3 development is planned for mid-2026, which could bring this therapy closer to market.
How to Prepare: Stay informed about developments in obesity treatments and consult with healthcare providers about available options.
Who This Affects Most: Individuals with obesity or overweight with at least one weight-related co-morbidity.
Discussion
Do you think this oral treatment will significantly impact the obesity epidemic? Let us know in the comments!
Share this article with others who need to stay ahead of this trend!
Related Articles
HealthNutrition
Harvard Study: Prioritizing High-Quality Carbs After 40 for Healthy Aging
A recent study from Harvard and Tufts University suggests that focusing on high-quality carbohydrates and fiber in your 40s can significantl...
about 1 month ago
HealthNutrition
Vitamin B1 'Crazy' Theory Confirmed & Eating Habits Linked to Weight
Two new studies shed light on how our bodies function and how our eating habits impact weight. One confirms a decades-old theory about Vitam...
2 months ago
HealthNutrition
Energy Drink Blamed in Cheerleader's Death: Lawsuit Filed
A wrongful death lawsuit has been filed against the distributors of Alani Nu energy drinks, alleging that the beverage contributed to the de...
2 months ago
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer